SMARCA2 and prostate carcinoma: For example, it has recently been shown that androgen receptor (AR) and forkhead box A1 (FOXA1) expressing prostate cancer cells are sensitive to simultaneous degradation of BAF complex subunits SMARCA2, SMARCA4 and PBRM131.